Frontiers in Oncology (Nov 2023)
Corrigendum: Development and validation of a m6A -regulated prognostic signature in lung adenocarcinoma
- Yaxin Chen,
- Lei Xia,
- Yuxuan Peng,
- Gang Wang,
- Liyun Bi,
- Xue Xiao,
- Cui Li,
- Weimin Li,
- Weimin Li,
- Weimin Li,
- Weimin Li
Affiliations
- Yaxin Chen
- Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
- Lei Xia
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, China
- Yuxuan Peng
- Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
- Gang Wang
- Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China
- Liyun Bi
- Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China
- Xue Xiao
- Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
- Cui Li
- Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
- Weimin Li
- Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
- Weimin Li
- Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China
- Weimin Li
- Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China
- Weimin Li
- The Research Units of West China, Chinese Academy of Medical Sciences, West China Hospital, Chengdu, China
- DOI
- https://doi.org/10.3389/fonc.2023.1309950
- Journal volume & issue
-
Vol. 13
Abstract
No abstracts available.Keywords